Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score

Abstract Background Cardiovascular complications are common in kidney transplant patients and calcification propensity of blood, measured as T50, is associated with cardiovascular outcomes. Paricalcitol supplementation affects calcium/phosphate homeostasis and may affect calcification propensity. To...

Full description

Bibliographic Details
Main Authors: Amin Ussif, Hege Pihlstrøm, Andreas Pasch, Hallvard Holdaas, Anders Hartmann, Knut Smerud, Anders Åsberg
Format: Article
Language:English
Published: BMC 2018-08-01
Series:BMC Nephrology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12882-018-1000-8
id doaj-43de48f2aaa343cc8df37dff9cf54efb
record_format Article
spelling doaj-43de48f2aaa343cc8df37dff9cf54efb2020-11-24T21:22:57ZengBMCBMC Nephrology1471-23692018-08-011911510.1186/s12882-018-1000-8Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity scoreAmin Ussif0Hege Pihlstrøm1Andreas Pasch2Hallvard Holdaas3Anders Hartmann4Knut Smerud5Anders Åsberg6Department of Transplantation Medicine, Oslo University Hospital RikshospitaletDepartment of Transplantation Medicine, Oslo University Hospital RikshospitaletCalciscon AGDepartment of Transplantation Medicine, Oslo University Hospital RikshospitaletDepartment of Transplantation Medicine, Oslo University Hospital RikshospitaletSmerud Medical Research International ASDepartment of Transplantation Medicine, Oslo University Hospital RikshospitaletAbstract Background Cardiovascular complications are common in kidney transplant patients and calcification propensity of blood, measured as T50, is associated with cardiovascular outcomes. Paricalcitol supplementation affects calcium/phosphate homeostasis and may affect calcification propensity. To assess this hypothesis we measured T50 in kidney transplant recipients participating in a randomized study comparing paricalcitol versus no treatment during the first year after kidney transplantation. Methods Stored serum samples from 76 kidney transplant recipients (paricalcitol n = 37, no treatment n = 39) were analyzed. Analyses were performed at inclusion (8 weeks after transplantation) and repeated one year after transplantation. Results There were no statistically significant differences in T50 between the paricalcitol and placebo groups, neither at baseline (p = 0.56) nor at 1 year (p = 0.61). Also, there were no significant changes in T50 over time in either group or when pooling all data (p <  0.20). In multivariate regression analysis, out of 16 potentially relevant covariates, comprising clinical and biochemical parameters, only plasma PTH and T50 at baseline were significantly correlated to T50 after one year. (p <  0.03 and p < 0.01, respectively). Conclusions Calcium propensity measured as T50 score remained unchanged with paricalcitol treatment in kidney transplant recipients, and was not changed over time during the study period of one year. Trial registration ClinicalTrials.gov, NCT01694160, registered 23 September 2012.http://link.springer.com/article/10.1186/s12882-018-1000-8ParicalcitolCalcification propensity scoreRandomized controlled trialRenal transplantation
collection DOAJ
language English
format Article
sources DOAJ
author Amin Ussif
Hege Pihlstrøm
Andreas Pasch
Hallvard Holdaas
Anders Hartmann
Knut Smerud
Anders Åsberg
spellingShingle Amin Ussif
Hege Pihlstrøm
Andreas Pasch
Hallvard Holdaas
Anders Hartmann
Knut Smerud
Anders Åsberg
Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
BMC Nephrology
Paricalcitol
Calcification propensity score
Randomized controlled trial
Renal transplantation
author_facet Amin Ussif
Hege Pihlstrøm
Andreas Pasch
Hallvard Holdaas
Anders Hartmann
Knut Smerud
Anders Åsberg
author_sort Amin Ussif
title Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
title_short Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
title_full Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
title_fullStr Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
title_full_unstemmed Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
title_sort paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
publisher BMC
series BMC Nephrology
issn 1471-2369
publishDate 2018-08-01
description Abstract Background Cardiovascular complications are common in kidney transplant patients and calcification propensity of blood, measured as T50, is associated with cardiovascular outcomes. Paricalcitol supplementation affects calcium/phosphate homeostasis and may affect calcification propensity. To assess this hypothesis we measured T50 in kidney transplant recipients participating in a randomized study comparing paricalcitol versus no treatment during the first year after kidney transplantation. Methods Stored serum samples from 76 kidney transplant recipients (paricalcitol n = 37, no treatment n = 39) were analyzed. Analyses were performed at inclusion (8 weeks after transplantation) and repeated one year after transplantation. Results There were no statistically significant differences in T50 between the paricalcitol and placebo groups, neither at baseline (p = 0.56) nor at 1 year (p = 0.61). Also, there were no significant changes in T50 over time in either group or when pooling all data (p <  0.20). In multivariate regression analysis, out of 16 potentially relevant covariates, comprising clinical and biochemical parameters, only plasma PTH and T50 at baseline were significantly correlated to T50 after one year. (p <  0.03 and p < 0.01, respectively). Conclusions Calcium propensity measured as T50 score remained unchanged with paricalcitol treatment in kidney transplant recipients, and was not changed over time during the study period of one year. Trial registration ClinicalTrials.gov, NCT01694160, registered 23 September 2012.
topic Paricalcitol
Calcification propensity score
Randomized controlled trial
Renal transplantation
url http://link.springer.com/article/10.1186/s12882-018-1000-8
work_keys_str_mv AT aminussif paricalcitolsupplementationduringthefirstyearafterkidneytransplantationdoesnotaffectcalcificationpropensityscore
AT hegepihlstrøm paricalcitolsupplementationduringthefirstyearafterkidneytransplantationdoesnotaffectcalcificationpropensityscore
AT andreaspasch paricalcitolsupplementationduringthefirstyearafterkidneytransplantationdoesnotaffectcalcificationpropensityscore
AT hallvardholdaas paricalcitolsupplementationduringthefirstyearafterkidneytransplantationdoesnotaffectcalcificationpropensityscore
AT andershartmann paricalcitolsupplementationduringthefirstyearafterkidneytransplantationdoesnotaffectcalcificationpropensityscore
AT knutsmerud paricalcitolsupplementationduringthefirstyearafterkidneytransplantationdoesnotaffectcalcificationpropensityscore
AT andersasberg paricalcitolsupplementationduringthefirstyearafterkidneytransplantationdoesnotaffectcalcificationpropensityscore
_version_ 1725994231098507264